Dissecting Key Updates in Non-Advanced Systemic Mastocytosis From ASH 2025

Lindsay Rein, MD, and Frederick Lansigan, MD, discuss current treatment standards for non-advanced systemic mastocytosis.

Lindsay Rein, MD, and Frederick Lansigan, MD, delve into the frequency of KIT D816V mutations in non-advanced systemic mastocytosis.

Lindsay Rein, MD, and Frederick Lansigan, MD, compare the profiles of the investigational agent bezuclastinib and the approved agent avapritinib in non-advanced systemic mastocytosis.

Lindsay Rein, MD, and Frederick Lansigan, MD, discuss data from the SUMMIT trial for bezuclastinib in non-advanced systemic mastocytosis.

Lindsay Rein, MD, and Frederick Lansigan, MD, discuss additional findings from the SUMMIT trial from ASH 2025 for bezuclastinib in non-advanced systemic mastocytosis.

Lindsay Rein, MD, and Frederick Lansigan, MD, detail other key data from ASH 2025 for non-advanced systemic mastocytosis and ongoing research to watch in the space.